Lakeway, TX -- (SBWIRE) -- 02/20/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
R.R. Donnelley & Sons Company (NASDAQ:RRD) shares gained 3.39% to $10.07 in the last trading session. The company announced that it will release its financial results for the fourth quarter and full year ended December 31, 2012 on Tuesday, February 26, before the market opens. On the same day, at 9:00am Central time, management will host a conference call to be broadcast simultaneously over the internet to review the company's results.
How Should Investors Trade RRD After The Latest Report? Find Out Here
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares increased 3.28% and closed at $6.29 in yesterday’s session. The company, last month, announced the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a vacancy on ACADIA's board and serve as a Class II director. The terms of the Class II directors will expire at the annual meeting of stockholders in 2015.
Is ACAD a Buy After The Recent News? Get Free Trend Analysis Here
Medtronic, Inc. (NYSE:MDT) shares decreased 2.80% and closed at $45.80 in yesterday’s session after the company yesterday reported a profit of $988 million, or 97 cents a share, up from $935 million, or 88 cents a share, a year earlier. Excluding acquisition-related charges and other items, adjusted earnings were 93 cents, better than the 91 cents projected by analysts. For the quarter ended Jan. 25, revenue increased 2.8% to $4.03 billion, missing analysts' expectations of $4.04 billion.
How Should Investors Trade MDT After The Recent Movement? Find Out Here
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares decreased 2.73% and closed at $160.42 in yesterday’s session. The company, last week, posted a net profit for the fourth quarter of $470 million or $4.08 per share, compared to a net loss of $53 million or $0.58 per share in the year-ago quarter. On a non-GAAP basis, profit was $171 million or $1.47 per share. Analysts expected the company to report earnings per share of $1.11 for the quarter. For the quarter, the Company's total revenues surged to $415 million from $123 million in the last year.
Additionally, Zacks reaffirmed their neutral rating on shares of Regeneron in a report issued on Feb. 18. They currently have a $173.00 target price on the stock.
Get Latest News, Updates and Reports For Free On REGN Here
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)